Novo Nordisk (NYSE: NVO) repurchases 20,959,179 shares in 2026

Rhea-AI Filing Summary

Novo Nordisk A/S provides an update on its ongoing share repurchase programme. As part of a broader plan to buy back up to DKK 15 billion of B shares over a 12-month period beginning 4 February 2026, the company is running a specific programme initiated on 6 May 2026 to repurchase up to DKK 11,200,000,010.45 of B shares through 1 February 2027.

Including transactions from 15–19 June 2026, the company has accumulated 6,200,000 B shares under this programme with a total transaction value of DKK 1,777,005,178. As of 19 June 2026, Novo Nordisk has repurchased 20,959,179 B shares since 4 February 2026 at an average price of DKK 266.09, equal to DKK 5,577,005,168. The company now holds 38,144,480 B shares as treasury shares, representing 0.9% of its 4,465,000,000 total A and B shares.

Key Figures

Overall buyback target: DKK 15,000,000,000 Sub-programme capacity: DKK 11,200,000,010.45 Shares under sub-programme: 6,200,000 B shares +5 more

8 metrics

Overall buyback target DKK 15,000,000,000 Total B share repurchases planned over 12 months from 4 February 2026

Sub-programme capacity DKK 11,200,000,010.45 Maximum B share repurchases from 6 May 2026 to 1 February 2027

Shares under sub-programme 6,200,000 B shares Accumulated repurchases under programme initiated 6 May 2026

Sub-programme value DKK 1,777,005,178 Total transaction value accumulated under the May 2026 programme

Total 2026 repurchases 20,959,179 B shares Shares repurchased since 4 February 2026 as of 19 June 2026

Average repurchase price DKK 266.09 per B share Average price for 20,959,179 B shares since 4 February 2026

Total repurchase value DKK 5,577,005,168 Transaction value of B share repurchases since 4 February 2026

Treasury share position 38,144,480 B shares (0.9%) Treasury B shares as a share of 4,465,000,000 total A and B shares

Key Terms

share repurchase programme, treasury shares, Safe Harbour Rules, foreign private issuer, +1 more

5 terms

share repurchase programme financial

"This programme is part of the overall share repurchase programme of up to DKK 15 billion"

A share repurchase programme is a company's plan to buy back its own shares from the market. This reduces the total number of shares available, which can increase the value of remaining shares and signal confidence in the company's health. For investors, it can indicate that the company believes its stock is undervalued and may lead to higher share prices.

treasury shares financial

"Novo Nordisk owns a total of 38,144,480 B shares of DKK 0.10 as treasury shares"

Treasury shares are a company’s own stock that it has repurchased and keeps on its books instead of canceling or leaving in the hands of outside investors. Think of them like coupons a business puts back in a drawer: they don’t vote or receive dividends while held, but they can be reissued later for employee pay or fundraising. For investors this matters because buybacks change the number of shares that count toward earnings and ownership, can boost per‑share metrics, and use corporate cash that might otherwise go to growth or dividends.

Safe Harbour Rules regulatory

"in accordance with ... the Commission Delegated Regulation (EU) 2016/1052 ... (the "Safe Harbour Rules")"

foreign private issuer regulatory

"REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16"

A foreign private issuer is a company organized outside the United States that meets tests showing it is primarily foreign-controlled and therefore qualifies for a different set of U.S. reporting rules. For investors, that means the company files less frequent or differently formatted disclosures with U.S. regulators and may follow home-country accounting and governance practices, so buying its stock is like dining at a well-reviewed restaurant that follows its home kitchen’s rules instead of the local menu — you get access but should check what standards apply.

ADR financial

"Its ADRs are listed on the New York Stock Exchange (NVO)."

An American Depositary Receipt (ADR) is a financial certificate that lets investors buy shares of a foreign company through U.S. stock markets, similar to buying a local wrapper that represents the underlying foreign shares. ADRs matter because they make investing in overseas companies easier and more liquid by trading in U.S. dollars and under U.S. market rules, while still carrying currency, regulatory, and country-specific risks that can affect share value.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 6-K: How Foreign Companies Report to the SEC →

Available on EDGAR 06/24/2026 - 06:03 AM Accepted by SEC EDGAR 06/24/2026 - 06:00 AM Learn about SEC filing dates

FAQ

How large is Novo Nordisk's 2026 share repurchase programme (NVO)?

Novo Nordisk plans to repurchase up to DKK 15 billion of B shares over a 12-month period starting 4 February 2026. This capital return programme is executed through buybacks conducted under market regulations and Safe Harbour Rules.

What is the size of Novo Nordisk's current B share buyback sub-programme?

Under the programme initiated on 6 May 2026, Novo Nordisk will repurchase B shares for up to DKK 11,200,000,010.45. The repurchase window runs from 6 May 2026 to 1 February 2027 as part of the broader DKK 15 billion plan.

How many Novo Nordisk B shares has the company repurchased in 2026 so far?

As of 19 June 2026, Novo Nordisk has repurchased a total of 20,959,179 B shares since 4 February 2026. The average purchase price is DKK 266.09 per B share, for a total transaction value of DKK 5,577,005,168.

How many Novo Nordisk shares are held as treasury shares after these buybacks?

Following the reported transactions, Novo Nordisk owns 38,144,480 B shares as treasury shares. This holding corresponds to 0.9% of the company’s total share capital of 4,465,000,000 A and B shares, including treasury shares.

What recent weekly buyback activity did Novo Nordisk report?

Between 15 and 19 June 2026, Novo Nordisk repurchased daily blocks of 190,000–225,000 B shares. Average purchase prices ranged from DKK 282.33 to DKK 293.48, contributing to an accumulated programme total of 6,200,000 B shares worth DKK 1,777,005,178.

On which exchanges are Novo Nordisk shares and ADRs traded?

Novo Nordisk’s B shares are listed on Nasdaq Copenhagen under the symbol Novo-B. Its American Depositary Receipts (ADRs) are listed on the New York Stock Exchange under the symbol NVO, giving international investors access to the company’s equity.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

________________

FORM 6-K

________________

REPORT OF FOREIGN PRIVATE ISSUER

Pursuant to Rule 13a-16 or 15d-16

of the Securities Exchange Act of 1934

June 22, 2026

________________

NOVO NORDISK A/S

 (Exact name of Registrant as specified in its charter)

Novo Allé 1

DK- 2880, Bagsvaerd

Denmark

(Address of principal executive offices)

________________

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F

Form 20-F ☒           Form 40-F ☐

 

 

Novo Nordisk A/S – Share repurchase programme

Bagsværd, Denmark, 22 June 2026 – On 6 May 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 15 billion to be executed during a 12-month period beginning 4 February 2026.

Under the programme initiated 6 May 2026, Novo Nordisk will repurchase B shares for an amount up to DKK 11,200,000,010.45 in the period from 6 May 2026 to 1 February 2027.

Since the announcement 15 June 2026, the following transactions have been made:

	Number of B shares	Average purchase price	Transaction value, DKK
Accumulated, last announcement	5,125,000		1,469,055,829
15 June 2026	225,000	286.10	64,371,831
16 June 2026	220,000	283.38	62,343,589
17 June 2026	220,000	288.00	63,360,172
18 June 2026	220,000	282.33	62,113,147
19 June 2026	190,000	293.48	55,760,610
Accumulated under the programme	6,200,000		1,777,005,178

The details for each transaction made under the share repurchase programme are published on novonordisk.com.

With the transactions stated above, Novo Nordisk owns a total of 38,144,480 B shares of DKK 0.10 as treasury shares, corresponding to 0.9% of the share capital. The total amount of A and B shares in the company is 4,465,000,000 including treasury shares.

Page 2 of 2

Novo Nordisk expects to repurchase B shares for an amount up to DKK 15 billion during a 12month period beginning 4 February 2026. As of 19 June 2026, Novo Nordisk has since 4 February 2026 repurchased a total 20,959,179 B shares at an average share price of DKK 266.09 per B share equal to a transaction value of DKK 5,577,005,168.

Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 68,800 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.

Contacts for further information

Media:
Ambre James-Brown		Liz Skrbkova (US)
+45 3079 9289		+1 609 917 0632
globalmedia@novonordisk.com		lzsk@novonordisk.com
Investors:
Michael Novod		Jacob Martin Wiborg Rode
+45 3075 6050		+45 3075 5956
nvno@novonordisk.com		jrde@novonordisk.com
Ida Schaap Melvold		Sina Meyer
+45 3077 5649		+45 3079 6656
idmg@novonordisk.com		azey@novonordisk.com
Alex Bruce		Christoffer Sho Togo Tullin
+45 3444 2613		+45 3079 1471
axeu@novonordisk.com		cftu@novonordisk.com
Frederik Taylor Pitter		Mads Berner Bruun
+1 609 613 0568		+45 3075 2936
fptr@novonordisk.com		mbbz@novonordisk.com

Novo Nordisk A/S Investor Relations	Novo Allé 1 2880 Bagsværd Denmark	Telephone: +45 4444 8888	www.novonordisk.com CVR no: 24 25 67 90
			Company announcement No 39 / 2026

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.

Date: June 22, 2026   NOVO NORDISK A/S   Maziar Mike Doustdar Chief Executive Officer